Will Big Pharma get the bug for microbiome therapies?
06-05-2020
Chinese institute tries to patent Gilead coronavirus drug
06-02-2020
Oleschwander / Shutterstock.com
Swiss-based Ferring Pharmaceuticals has prevailed in a patent dispute with rivals Serenity Pharmaceuticals and Reprise Biopharmaceuticals over a nighttime urination, or nocturia, treatment.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Ferring, Serenity, Reprise, Nocdurna, desmopressin, FDA, nocturia, patents, invalidation, inventor
